Skip to main content

Treatment Clinical Trials for Recurrent Brain Neoplasm

Review the recurrent brain neoplasm treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 30

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Status: Active
Location: 39 locations
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Status: Active
Location: 33 locations
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Status: Active
Location: 19 locations
Tocilizumab for the Treatment of Progressive or Recurrent Pediatric Adamantinomatous Craniopharyngioma
Status: Active
Location: 6 locations
Binimetinib for the Treatment of Pediatric Progressive or Recurrent Adamantinomatous Craniopharyngioma
Status: Active
Location: 4 locations
Digoxin for the Treatment of Pediatric and Young Adult Patients with Relapsed Non-SHH, Non-WNT Medulloblastoma
Status: Active
Location: 7 locations
A Peptide Vaccine (PEP-CMV) for the Treatment of Pediatric Patients with Newly Diagnosed High-Grade Glioma and Diffuse Intrinsic Pontine Glioma, or Recurrent, Refractory, or Progressive Medulloblastoma
Status: Active
Location: 4 locations
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Location: 6 locations
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Location: 3 locations
ACT001 for the treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) and Progressive, Refractory, or Recurrent DIPG or H3K27-Altered High Grade Gliomas
Status: Active
Location: 2 locations
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Status: Active
Location: 2 locations
Intra-arterial Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treating Patients Under 22 Years of Age with Relapsed or Refractory Intracranial Glioma
Status: Active
Location: 2 locations
Genetically Engineered Cells (C7R-GD2.CAR T Cells) for the Treatment of Patients with GD2-Expressing High Grade Glioma or Diffuse Intrinsic Pontine Glioma, The GAIL-B Trial
Status: Active
Location: 2 locations
Atovaquone Alone or Combined with Radiation for the Treatment of Children with Malignant Brain Tumors
Status: Active
Location: 2 locations
Palbociclib and Pembrolizumab for the Treatment of Patients with Brain Metastases
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Lerapolturev versus Lomustine for the Treatment of Recurrent GBM
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancer
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Ivonescimab for the Treatment of Patients with Recurrent Glioblastoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Dapagliflozin in Combination with Standard Chemotherapy for the Treatment of Recurrent Brain Tumors or Relapsed or Refractory Solid Tumors in Pediatric Patients
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma
Status: Active
Location: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania
Personalized DNA Vaccine for the Treatment of Patients with Recurrent or Refractory Pediatric Central Nervous System Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Cellular Therapy (GPC2-CAR T-Cells) for the Treatment of Children and Young Adults with Relapsed or Refractory Medulloblastoma and other Central Nervous System Embryonal Tumors
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Intraventricular Infusion of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) for the Treatment of Recurrent or Refractory Glioblastoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
WP1066 for the Treatment of Recurrent or Refractory and Progressive Malignant Brain Tumors
Status: Active
Location: Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia
Intrathecal Azacitidine and Nivolumab for the Treatment of Patients with Recurrent High-Grade Glioma
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa